Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Equillium, Inc. (NASDAQ:EQ) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 153,600 shares, a growth of 30.6% from the October 31st total of 117,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 182,900 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Equillium in a research note on Monday, August 19th.

Equillium Price Performance

Shares of NASDAQ:EQ opened at $0.75 on Monday. Equillium has a fifty-two week low of $0.48 and a fifty-two week high of $3.25. The company has a market capitalization of $26.61 million, a price-to-earnings ratio of -5.36 and a beta of 1.83. The firm’s 50 day simple moving average is $0.88 and its 200 day simple moving average is $0.90.

Insider Activity at Equillium

In related news, insider Penny Tom sold 38,806 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $0.85, for a total value of $32,985.10. Following the completion of the sale, the insider now owns 10,051 shares of the company’s stock, valued at $8,543.35. This trade represents a 79.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 77,324 shares of company stock valued at $71,233 in the last three months. Corporate insiders own 30.30% of the company’s stock.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC lifted its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,400 shares of the company’s stock after purchasing an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned 0.85% of Equillium worth $208,000 at the end of the most recent quarter. Institutional investors own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.